This is a prospective observational cohort study that will create a patient registry by collecting data on patients who receive REBYOTA to prevent recurrence of Clostridioides difficile infection (CDI). The registry will include data about CDI episodes, CDI related symptoms, healthcare resource utilization (i.e., hospitalizations and re-admissions) and this data will be collected up to 6-months after receiving REBYOTA™.

This is an observational study that create a patient registry by collecting data, biosamples (blood and stool samples) on patients who have been diagnosed with Clostridiodes difficile (C difficile). The registry will include data about CDI episodes, CDI related symptoms, participant experience. The study will last 42 days and there will be 2-3 visits.